Protagonist Therapeutics (PTGX) Revenue (2017 - 2026)

Protagonist Therapeutics has disclosed Revenue across 10 years of filings, most recently posting $56.4 million for Q1 2026.

• Revenue for Q1 2026 came in at $56.4 million, up 99.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $74.1 million (down 63.36% YoY), and the FY2025 annual result was $46.0 million, down 89.41% from the prior year.
• Revenue came in at $56.4 million for Q1 2026 at Protagonist Therapeutics, up from $7.4 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $255.0 million in Q1 2024 to a low of -$19000.0 in Q4 2022.
• The 5-year median for Revenue is $7.4 million (2025), against an average of $43.7 million.
• Across the five-year window, Revenue tumbled 100.22% in 2022 and jumped 52731.58% in 2023, its largest moves.
• Protagonist Therapeutics' Revenue stood at -$19000.0 in 2022, then surged by 52731.58% to $10.0 million in 2023, then soared by 1550.0% to $165.0 million in 2024, then sank by 95.49% to $7.4 million in 2025, then jumped by 657.94% to $56.4 million in 2026.
• The last three Revenue figures came in at $56.4 million (Q1 2026), $7.4 million (Q4 2025), and $4.7 million (Q3 2025), per Business Quant data.